BerGenBio is currently collaborating with several leading pharmaceutical companies and academic institutions to advance the development of bemcentinib. These Collaborators include Merck & Co. (MSD), ADC Therapeutics, Massachusetts Institute of Technology, Harvard Medical School, MD Anderson Cancer Center, University of Texas Southwestern Medical Center, and Haukeland University Hospital (Bergen).
BerGenBio retains full global development, marketing and commercialisation rights for its product candidates. As we further advance our selective small molecule AXL inhibitor bemcentinib (BGB324) and other drug candidates in our pipeline, we will seek partners to maximise clinical and commercial opportunities worldwide.
Please direct enquiries to Richard Godfrey, CEO.